Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.36 |
| ▸ | LAP3 | P28838 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IARS1 | P41252 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722209 | 0.88 | LAP3 (0.44) | DPP4DPP8DPP9LAP3CYP2D6 | |
| SCHEMBL3725774 | 0.88 | LAP3 (0.44) | DPP4DPP8DPP9LAP3CYP2D6 | |
| SCHEMBL30474563 | 0.82 | DPP4 (0.40) | DPP4DPP8DPP9LAP3METAP1 | |
| SCHEMBL29761142 | 0.80 | LAP3 (0.35) | LAP3CYP2D6CYP2C9CYP2C19SLC7A5 | |
| SCHEMBL28044917 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP9IARS1DPP7 | |
| SCHEMBL1446935 | 0.78 | DPP4 (0.42) | DPP4DPP8DPP9IARS1DPP7 | |
| SCHEMBL3722214 | 0.74 | SLC7A5 (0.42) | DPP4DPP8DPP9LAP3DPP7 | |
| SCHEMBL1758772 | 0.74 | LAP3 (0.46) | DPP4DPP8DPP9LAP3DPP7 | |
| SCHEMBL2783500 | 0.73 | DPP4 (0.47) | DPP4DPP8DPP9IARS1DPP7 | |
| SCHEMBL3930248 | 0.72 | DPP4 (0.46) | DPP4DPP8DPP9IARS1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779012-B2 | Compositions and methods for preserving red blood cells and platelets | RYTHRX THERAPEUTICS, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220248666-A1 | COMPOSITIONS AND METHODS FOR PRESERVING RED BLOOD CELLS AND PLATELETS | RYTHRX THERAPEUTICS, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11344026-B2 | Compositions and methods for preserving red blood cells and platelets | RYTHRX THERAPEUTICS, LLC (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344026-B2 | Compositions and methods for preserving red blood cells and platelets | RCN1, THPO, TYMP | DPP4 4386/4885DPP8 3935/4885DPP9 3564/4885 |
| US-11779012-B2 | Compositions and methods for preserving red blood cells and platelets | RCN1, THPO, TYMP | DPP4 4386/4885DPP8 3935/4885DPP9 3564/4885 |
| US-20220248666-A1 | COMPOSITIONS AND METHODS FOR PRESERVING RED BLOOD CELLS AND PLATELETS | RCN1, THPO, TYMP | DPP4 4386/4885DPP8 3935/4885DPP9 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.